Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and Perspectives

• Published in: The journal of clinical endocrinology and metabolism 2012-02, Vol.97 (2), p.311-325
• Main Authors: Baron, Roland, Hesse, Eric
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Anabolic Agents - therapeutic use; Antibodies; Biological and medical sciences; Bone Density Conservation Agents - therapeutic use; Bone mass; Bone mineral density; Bone Remodeling - drug effects; Bone Remodeling - physiology; Bone remodelling; Bone resorption; Bone turnover; Clinical trials; Drugs; Endocrinology - methods; Endocrinology - trends; Endocrinopathies; Estrogen receptors; Feeding. Feeding behavior; Female; Forearm; Fractures; Fundamental and applied biological sciences. Psychology; Hip; Humans; Male; Medical sciences; Middle Aged; Models, Biological; Osteogenesis; Osteoporosis; Osteoporosis - drug therapy; Parathyroid hormone; Rationalization; Signal transduction; Socio-economic aspects; SOST protein; Spine; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Vertebrates: endocrinology
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2011-2332

Osteoporosis is defined as low bone mineral density associated with skeletal fractures secondary to minimal or no trauma, most often involving the spine, the hip, and the forearm. The decrease in bone mineral density is the consequence of an unbalanced bone remodeling process, with higher bone resorption than bone formation. Osteoporosis affects predominantly postmenopausal women, but also older men. This chronic disease represents a considerable medical and socioeconomic burden for modern societies. The therapeutic options for the treatment of osteoporosis have so far comprised mostly antiresorptive drugs, in particular bisphosphonates and more recently denosumab, but also calcitonin and, for women, estrogens or selective estrogen receptor modulators. These drugs have limitations, however, in particular the fact that they lead to a low turnover state where bone formation decreases with the decrease in bone-remodeling activity. In this review, we discuss the alternative class of osteoporosis drugs, i.e. bone anabolics, their biology, and the perspectives they offer for our therapeutic armamentarium. We focus on the two main osteoanabolic pathways identified as of today: PTH, the only anabolic drug currently on the market; and activation of canonical Wnt signaling through inhibition of the endogenous inhibitors sclerostin and dickkopf1. Each approach is based on a different molecular mechanism, but most recent evidence suggests that these two pathways may actually converge, at least in part. Whereas recombinant human PTH treatment is being revisited with different formulations and attempts to regulate endogenous PTH secretion via the calcium-sensing receptor, antibodies to sclerostin and dickkopf1 are currently in clinical trials and may prove to be even more efficient at increasing bone mass, possibly independent of bone turnover. Each of these anabolic approaches has its own limitations and safety issues, but the prospects of effective anabolic therapy for osteoporosis are indeed bright.